Related Experiment Video
Updated: Jul 16, 2026

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
Published on: August 8, 2022
Myozenin 2 is a novel gene for human hypertrophic cardiomyopathy
Adriana Osio1, Lily Tan, Suet N Chen
1Center for Cardiovascular Genetic Research, The Brown Foundation Institute of Molecular Medicine, University of Texas Health Sciences Center, Houston, TX 77030, USA.
Insights
Genetic mutations in MYOZ2 cause hypertrophic cardiomyopathy (HCM), a heart muscle disorder. This study identifies MYOZ2 as a novel gene linked to HCM, expanding our understanding of its genetic basis.
Area of Science:
- Genetics
- Cardiology
- Molecular Biology
Background:
- Hypertrophic cardiomyopathy (HCM) is a genetic heart disorder often caused by sarcomeric protein mutations.
- The genetic cause for approximately one-third of HCM cases remains unknown, highlighting the need for further gene discovery.
Purpose of the Study:
- To identify novel causal genes for hypertrophic cardiomyopathy (HCM) in families with unknown genetic etiology.
- To investigate the role of myozenin 2 (MYOZ2) as a potential candidate gene for HCM.
Main Methods:
- Locus-specific haplotyping was performed to map the disease gene in a family with affected members.
- Short-tandem-repeat markers were genotyped to analyze linkage to the 4q26-q27 locus, encompassing MYOZ2.
- Mutation screening involved sequencing MYOZ2 exons and exon-intron boundaries in affected individuals and controls.
Main Results:
- Haplotype analysis implicated MYOZ2 on chromosome 4q26-q27 in HCM inheritance within the studied family.
- A novel T>C missense mutation (S48P) in MYOZ2 was identified in all affected family members and cosegregated with HCM.
- A second missense mutation (I246M) in MYOZ2 was found in additional HCM probands, suggesting MYOZ2 as a recurrent cause of HCM.
Conclusions:
- MYOZ2 is identified as a novel causal gene for human hypertrophic cardiomyopathy.
- Mutations in MYOZ2 contribute to the genetic landscape of HCM, particularly in cases with unknown genetic origins.
- These findings expand the spectrum of genes associated with HCM and provide new insights into its molecular pathogenesis.
Abstract:
Hypertrophic cardiomyopathy (HCM) is a genetic disorder caused by mutations in sarcomeric proteins (excluding phenocopy). The causal genes in approximately one-third of the cases remain unknown. We identified a family comprised of 6 clinically affected members. The phenotype was characterized by early onset of symptoms, pronounced cardiac hypertrophy, and cardiac arrhythmias. We excluded MYH7, MYBPC3, TNNT2, and ACTC1 as the causal gene either by direct sequencing or by haplotype analysis. To map the putative candidate sarcomeric gene, we perforbold locus-specific haplotyping to detect cosegregation of the locus haplotype with the phenotype, followed by mutation screening. We genotyped 5 short-tandem-repeat markers that spanned a 4.4-centimorgan region on 4q26-q27 locus and encompassed myozenin 2 (MYOZ2), a Z-disk protein. The maximum logarithm of odds score was 2.03 (P=0.005). All affected members shared a common haplotype, implicating MYOZ2 as the causal gene. To detect the causal mutation, we sequenced all exons and exon-intron boundaries of MYOZ2 in 10 family members and identified a T-->C missense mutation corresponding to S48P substitution, which cosegregated with inheritance of HCM (N=6). It was absent in 4 clinically normal family members and in 658 additional normal individuals. To determine frequency of the MYOZ2 mutations in HCM, we sequenced MYOZ2 in 516 HCM probands and detected another missense mutation (I246M). It was absent in 2 normal family members and 517 controls. Both mutations affect highly conserved amino acids. We conclude MYOZ2 is a novel causal gene for human HCM.
Related Concept Videos
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy IV: Restrictive Cardiomyopathy
Cardiomyopathy I: Introduction and Classification
Cellular Adaptation II: Hypertrophy
Hypertension II: Pathophysiology

